FOLH1 and cancer: In cancer therapy, BIND-014, a nanoparticle designed to deliver docetaxel with a hydrophilic PEG targeting the prostate-specific membrane antigen (PSMA), aimed to treat various cancers, including prostate, non-small-cell lung, and advanced cervical, head, and neck cancers.